



"APPROVED"

**Executive Director of State
Health Insurance Fund**

Z.Sh.Ermatov

30 December 2025 year

Terms of reference and conditions

#	Customer:	State Health Insurance Fund
2	Contents of selection	Selection of the best proposals for determining the marginal cost of reimbursement of medicines (in terms of the form of release, dose, and international nonproprietary name (INN) provided based on the reimbursement program
3	Selection type	Selecting the best offer
4	Source for downloading the selection documentation	https://dtsj.uz/uz/reimbursatsiya/ For more information: +998 71 207 19 23 (112);
5	Documents submitted for participation in the selection	1. Provision of a registration certificate and a certificate of conformity for each medicinal product according to INN, trade name, form of release and dosage (Appendix #1) 2. Submission of a competitive price offer for each medicinal product according to INN, trade name, form of release, and dosage (Appendix #2). In this case, the competitive price offer should not exceed the reference price for this medicinal product according to INN, trade name, form of release, and dosage. 3. Provision of a letter of guarantee on prevention of corruption risks.
6	Time and address of receiving bids	Competitive price offers are provided by e-mail (reimbursement@dtsj.uz) within 10 (ten) business days from the date this announcement is posted for each medicinal product in the context of INN, trade name, form of release, and dosage.
7	The procedure and deadline for evaluating bids	1. Competitive price proposals will be reviewed within 5 (five) business days after the deadline for submitting competitive proposals at a meeting of the Commission formed under the State Health Insurance Fund. 2. Based on competitive price proposals, a list of prices is formed in ascending order by INN, trade names, forms of release, and dosages. Then, starting from the lowest price

	index, 5 (five) medicines are selected by trade name, form of release, and dosage. 3. Based on the proposed price, the maximum cost of reimbursement is set for the trade name, form, and dose of the selected medicines. At the same time, the proposed price, retail trade allowance, and VAT are taken into account as part of the marginal cost of reimbursement. 4. The highest marginal cost of reimbursement among the selected medicines is taken as the highest marginal cost of reimbursement for INN, form, and dose of this medicinal product. 5. Suppliers who have submitted their proposals to the State Medical Insurance Fund are notified of the accepted marginal cost of reimbursement for INN, form, and dose of the corresponding drug through the State Health Insurance Fund's website (https://dtsj.uz/ru/reimbursatsiya). Suppliers who have offered prices exceeding the maximum cost of compensation are allowed to change the prices indicated in their offer to prices not exceeding the maximum cost of compensation, and within 48 hours to submit updated offers by the established procedure to the e-mail of the State Medical Insurance Fund. (reimbursement@dtsj.uz). 6. The Commission shall consider the updated proposals within 2 (two) working days and, together with the preliminary meeting results, approve the list of medicines with an appropriate protocol indicating the trade name, form, and dose of medicines and the marginal cost of reimbursement for each INN, form, and dose of medicines. 7. The minutes of the Commission's meeting and the approved list of trade names, forms, and dosages of medicines, as well as the maximum cost of reimbursement, are published on the website of the State Health Insurance Fund (https://dtsj.uz/ru/reimbursatsiya /) and social media pages on the next business day after signing this protocol.
--	---

List of medicines provided based on the reimbursement program by dosage form and dosage

#	International nonproprietary name	Form and dosage
I. Drugs used to treat pathologies of the gastrointestinal tract Proton Pump Inhibitors		
<i>Proton Pump Inhibitors</i>		
1	Omeprazole	20 mg capsule
	Omeprazole	40 mg capsule
II. Drugs that affect peripheral adrenergic processes		
<i>Drugs used for anti-asthmatic and chronic obstructive pulmonary disease</i>		
2	Salbutamol	aerosol 100 mcg/dose 7 g 200 dose
III. Drugs used to treat pathologies of the endocrine system		
<i>Iodine preparations</i>		
3	Potassium iodide	200 mcg tablet
<i>Antithyroid drugs</i>		
4	Thiamazole	5 mg tablet
<i>Thyroid hormones</i>		
5	Levothyroxine sodium	tablet of 100 mcg
<i>Thyroid hormones</i>		
6	Desmopressin	nasal drops 100 mcg/ml 5 ml
		metered nasal spray 10 mcg/ dose 5 ml
<i>Anti-diabetes drugs</i>		
7	Gliclazide	tablet 30 mg
	Gliclazide	tablet 60 mg
8	Metformin	tablet 500 mg
	Metformin	tablet 1000 mg
9	Empagliflozin	tablet 10 mg
	Empagliflozin	tablet 25 mg
<i>Glucocorticoids (hormones of the adrenal cortex)</i>		
10	Prednisone	tablet 5 mg
IV.Expectorant agents		
11	Ambroxol	tablet 30 mg
V. Medicines that affect the cardiovascular system		
<i>Antiarrhythmic drugs</i>		
12	Verapamil	tablet 80 mg
<i>Antianginal drugs</i>		
13	Isosorbide dinitrate	spray 1.25 mg/dose, 15 mL, 300 doses
		tablet 10 mg
14	Isosorbite mononitrate	20 mg tablet
	Isosorbite mononitrate	40 mg tablet
<i>Antiplatelet agents</i>		
15	Acetylsalicylic acid	tablet 75 mg
	Acetylsalicylic acid	tablet 150 mg
16	Clopidogrel	tablet 75 mg
<i>Selective β1-adrenoreceptor blockers</i>		
17	Bisoprolol	tablet 2,5 mg
	Bisoprolol	tablet 5 mg
	Bisoprolol	tablet 10 mg

<i>Hypolipidemic agents</i>		
18	Atorvastatin	tablet 10 mg
	Atorvastatin	tablet 20 mg
	Atorvastatin	tablet 40 mg
	Atorvastatin	tablet 80 mg
VI. Antihypertensive agents		
<i>Calcium channel blockers</i>		
19	Amlodipine	tablet 2.5 mg
	Amlodipine	tablet 5 mg
	Amlodipine	tablet 10 mg
<i>Angiotensin converting enzyme inhibitors</i>		
20	Enalapril maleat	tablet 2.5 mg
	Enalapril maleat	tablet 5 mg
	Enalapril maleat	tablet 10 mg
	Enalapril maleat	tablet 20 mg
VII. Agents that affect platelet aggregation and blood clotting		
21	Warfarin	tablet 2.5 mg
VIII. Diuretic and antidiuretic agents		
22	Spironolactone	tablet 2.5 mg
23	Furosemide	tablet 40 mg
IX. Vitamins and their derivatives		
<i>Vitamins</i>		
24	Folic acid	tablet 1 mg
	Folic acid	tablet 5 mg
X. Drugs that stimulate erythropoiesis		
25	Ferrous iron preparations (Fe^{2+})	tablet 100 mg
	Ferrous iron preparations (Fe^{2+})	capsule 100 mg
26	Ferric iron preparations (Fe^{3+})	tablet 100 mg
	Ferric iron preparations (Fe^{3+})	capsule 100 mg
XI. Immunomodulators and antiviral agents		
27	Inosine pranobex	tablet 500 mg
XI. Anthelmintic agents		
28	Albendazole	tablet 200 mg
	Albendazole	tablet 400 mg
	Albendazole	Suspension

Submission of competitive proposals

#	INN	Trade name	Form and dosage	Price
1				
2				
...				

date

Note: *Name of the organization* _____ *Full name of the supervisor*
seal (signature) date

Note: Suggestions must be signed, scanned (PDF-file) and are presented with the Excel file application (**price offers are provided with wholesale markup without VAT and retail markup**).